CDC42 and cancer: We now provide pharmacological evidence that the CTD Ser2 and Ser5 phosphorylation status could be altered by inhibitors of Ras, as well as Rho, Rac and Cdc42, in human cancer cell lines, supporting a common theme for the Ras superfamily of GTPases-mediated modulation of the Pol II CTD code.